United States

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

3:59pm EST
Change (% chg)

$-0.04 (-0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive,... (more)


Beta: --
Market Cap(Mil.): $541.78
Shares Outstanding(Mil.): 107.71
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 185.06 15.80
EPS (TTM): -- -- --
ROI: -- -10.84 12.07
ROE: -- -39.67 16.02

BRIEF-Axovant announces second fiscal quarter results

* Axovant announces second fiscal quarter financial results and corporate updates

Nov 02 2017

Axovant to pull plug on Alzheimer's drug after key study fails

Drug developer Axovant Sciences Ltd said it would stop testing its lead drug in Alzheimer's after it failed to meet the main goals of a late-stage trial, underlining the challenges in developing treatments for the memory-robbing disease.

Sep 26 2017

UPDATE 3-Axovant to pull plug on Alzheimer's drug after key study fails

* Shares hit record low (Adds details, conference call and analyst comments; updates shares)

Sep 26 2017

BRIEF-Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease

* At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition

Sep 26 2017

Axovant's Alzheimer's drug fails late-stage trial

Sept 26 Axovant Sciences Ltd said on Tuesday its experimental drug targeting Alzheimer's patients failed to meet the main goals in a late-stage trial.

Sep 26 2017

Earnings vs. Estimates